Breast Cancer

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.

Joyce A. O’Shaughnessy, MD, the 2016 Giant of Cancer Care® for Community Outreach/Education, explains her continued commitment to impacting change in the space and aiding other oncologists.

Androgen recepter positivity serves as an independent predictor of beneficial outcomes in breast cancer.

The administration of daily aspirin did not improve invasive disease-free survival in patients with high-risk, HER2-negative breast cancer.

Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.

Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.

Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.

A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.

Jennifer M. Matro, MD provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice.

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

The addition of dalpiciclib to fulvestrant significantly prolonged progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to data from an interim analysis of the phase 3 DAWNA-1 trial.

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

John T. Cole, MD, discusses how updates in HER2-positive breast cancer have affected sequencing strategies, selecting between CDK4/6 inhibitors in the adjuvant and metastatic settings of hormone receptor HR–positive breast cancer, and the need for additional therapies in triple-negative breast cancer.

Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.

Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.

A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.

Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

A brief review of patient monitoring and screening practices in the setting of HER2+ metastatic breast cancer.

Taking into account a patient case of HER2+ metastatic breast cancer, experts review current frontline treatment options.

A subtle superstar, Nancy E. Davidson, MD, is as adept at conducting groundbreaking research as she is at treating patients and corralling investigators.

Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.

Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.